Literature DB >> 12595585

Myoclonic epilepsy in Gaucher disease: genotype-phenotype insights from a rare patient subgroup.

Joseph K Park1, Eduard Orvisky, Nahid Tayebi, Christine Kaneski, Mary E Lamarca, Barbara K Stubblefield, Brian M Martin, Raphael Schiffmann, Ellen Sidransky.   

Abstract

Gaucher disease, the inherited deficiency of lysosomal glucocerebrosidase, presents with a wide spectrum of manifestations. Although Gaucher disease has been divided into three clinical types, patients with atypical presentations continue to be recognized. A careful phenotypic and genotypic assessment of patients with unusual symptoms may help define factors that modify phenotype in this disorder. One such example is a rare subgroup of patients with type 3 Gaucher disease who develop progressive myoclonic epilepsy. We evaluated 16 patients with myoclonic epilepsy, nine of whom were diagnosed by age 4 y with severe visceral involvement and myoclonus, and seven with a more chronic course, who were studied between ages 22 and 40. All of the patients had abnormal horizontal saccadic eye movements. Fourteen different genotypes were encountered, yet there were several shared alleles, including V394L (seen on two alleles), G377S (seen on three alleles), and L444P, N188S, and recombinant alleles (each found on four alleles). V394L, G377S, and N188S are mutations that have previously been associated with non-neuronopathic Gaucher disease. The spectrum of genotypes differed significantly from other patients with type 3 Gaucher disease, where genotypes L444P/L444P and R463C/null allele predominated. Northern blot studies revealed a normal glucocerebrosidase transcript, whereas Western studies showed that the patients studied lacked the processed 56 kD isoform of the enzyme, consistent with neuronopathic Gaucher disease. Brain autopsy samples from two patients demonstrated elevated levels of glucosylsphingosine, a toxic glycolipid, which could contribute to the development of myoclonus. Thus, although there were certain shared mutant alleles found in these patients, both the lack of a shared genotype and the variability in clinical presentations suggest that other modifiers must contribute to this rare phenotype.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12595585     DOI: 10.1203/01.PDR.0000049515.79882.94

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  23 in total

Review 1.  The clinical management of Type 2 Gaucher disease.

Authors:  Karin Weiss; Ashley Gonzalez; Grisel Lopez; Leah Pedoeim; Catherine Groden; Ellen Sidransky
Journal:  Mol Genet Metab       Date:  2014-11-14       Impact factor: 4.797

2.  Progressive myoclonus epilepsies-Residual unsolved cases have marked genetic heterogeneity including dolichol-dependent protein glycosylation pathway genes.

Authors:  Carolina Courage; Karen L Oliver; Eon Joo Park; Jillian M Cameron; Kariona A Grabińska; Mikko Muona; Laura Canafoglia; Antonio Gambardella; Edith Said; Zaid Afawi; Betul Baykan; Christian Brandt; Carlo di Bonaventura; Hui Bein Chew; Chiara Criscuolo; Leanne M Dibbens; Barbara Castellotti; Patrizia Riguzzi; Angelo Labate; Alessandro Filla; Anna T Giallonardo; Geza Berecki; Christopher B Jackson; Tarja Joensuu; John A Damiano; Sara Kivity; Amos Korczyn; Aarno Palotie; Pasquale Striano; Davide Uccellini; Loretta Giuliano; Eva Andermann; Ingrid E Scheffer; Roberto Michelucci; Melanie Bahlo; Silvana Franceschetti; William C Sessa; Samuel F Berkovic; Anna-Elina Lehesjoki
Journal:  Am J Hum Genet       Date:  2021-04-01       Impact factor: 11.025

3.  EEG abnormalities in patients with chronic neuronopathic Gaucher disease: A retrospective review.

Authors:  Chelsie N Poffenberger; Sara Inati; Nahid Tayebi; Barbara K Stubblefield; Emory Ryan; Raphael Schiffmann; Ellen Sidransky; Grisel Lopez
Journal:  Mol Genet Metab       Date:  2020-10-20       Impact factor: 4.797

Review 4.  Neuropathic Gaucher disease.

Authors:  Gregory M Pastores
Journal:  Wien Med Wochenschr       Date:  2010-12

5.  Recent advances in the diagnosis and management of Gaucher disease.

Authors:  Sam E Gary; Emory Ryan; Alta M Steward; Ellen Sidransky
Journal:  Expert Rev Endocrinol Metab       Date:  2018-03-12

Review 6.  Gaucher disease: Progress and ongoing challenges.

Authors:  Pramod K Mistry; Grisel Lopez; Raphael Schiffmann; Norman W Barton; Neal J Weinreb; Ellen Sidransky
Journal:  Mol Genet Metab       Date:  2016-11-17       Impact factor: 4.797

Review 7.  A severity scoring tool to assess the neurological features of neuronopathic Gaucher disease.

Authors:  E H Davies; R Surtees; C DeVile; I Schoon; A Vellodi
Journal:  J Inherit Metab Dis       Date:  2007-09-16       Impact factor: 4.982

8.  Array-based gene discovery with three unrelated subjects shows SCARB2/LIMP-2 deficiency causes myoclonus epilepsy and glomerulosclerosis.

Authors:  Samuel F Berkovic; Leanne M Dibbens; Alicia Oshlack; Jeremy D Silver; Marina Katerelos; Danya F Vears; Renate Lüllmann-Rauch; Judith Blanz; Ke Wei Zhang; Jim Stankovich; Renate M Kalnins; John P Dowling; Eva Andermann; Frederick Andermann; Enrico Faldini; Rudi D'Hooge; Lata Vadlamudi; Richard A Macdonell; Bree L Hodgson; Marta A Bayly; Judy Savige; John C Mulley; Gordon K Smyth; David A Power; Paul Saftig; Melanie Bahlo
Journal:  Am J Hum Genet       Date:  2008-02-28       Impact factor: 11.025

Review 9.  Gaucher disease: insights from a rare Mendelian disorder.

Authors:  Ellen Sidransky
Journal:  Discov Med       Date:  2012-10       Impact factor: 2.970

10.  A novel alteration in metaxin 1, F202L, is associated with N370S in Gaucher disease.

Authors:  Mary E LaMarca; Mona Goldstein; Nahid Tayebi; Mauricio Arcos-Burgos; Brian M Martin; Ellen Sidransky
Journal:  J Hum Genet       Date:  2004-03-13       Impact factor: 3.172

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.